focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Substantial Shareholding

19 Jun 2008 17:26

RNS Number : 1421X
ReGen Therapeutics PLC
19 June 2008
 
 
19th June 2008
 
REGEN THERAPEUTICS PLC
(“ReGen” or the “Company”; Ticker: (RGT))
 
 
TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
 
 
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):
 
ReGen Therapeutics Plc
 
2. Reason for the notification:
 
An acquisition or disposal of voting rights
 
3. Full name of person(s) subject to the notification obligation (iii):
 
Andrew Clement Wilson
 
4. Full name of shareholder(s) (if difference from 3):
 
As above
 
5. Date of the transaction and date on which the threshold is crossed or reached (v):
 
18 June 2008
 
6. Date on which issued notified:
 
19 June 2008
 
7. Threshold(s) that is/are crossed or reached:
 
13%
8. Notified details
 
A: Voting rights attached to shares
 
Class/type of share if possible using the ISIN Code GB00B28XMY25
 
Situation Previous to the triggering transaction (vi) –
Number of Shares 1,477,000
Number of Voting Rights (viii) 1,477,000
 
Resulting situation after the triggering transaction (viii) –
Number of Shares 1,495,000
Number of Voting Rights – Direct (x) 1,495,000
Number of Voting Rights – Indirect (xi) N/A
% of voting rights – Direct 13.02%
% of voting rights – Indirect N/A
B: Financial Instruments
Resulting situation after the triggering transaction (xii)
 
Type of financial instrument N/A
 
Expiration date (xiii) N/A
 
Exercise/Conversion Period/Date (xiv) N/A
 
Number of voting rights that may be acquired if the
instrument is exercised/converted N/A
 
% of voting rights N/A
Total (A+B)
 
Number of voting rights 1,495,000
 
% of voting rights 13.02
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):
 
Shares are held in own name
 
Proxy Voting:
 
10. Name of the proxy holder: N/A
 
11. Number of voting rights proxy holder will cease to hold: N/A
 
12. Date on which proxy holder will cease to hold voting rights: N/A
 
13. Additional information: N/A
 
14. Contact name: N/A
 
15. Contact telephone number: N/A
 
 
For further information:
 
Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 207 153 4920
 
Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel: +44(0) 207 628 3396

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKCKDABKDCAD
Date   Source Headline
17th Sep 20207:00 amRNSClinical Study with Nasally Administered Foralumab
16th Sep 20209:05 amRNSSecond Price Monitoring Extn
16th Sep 20209:00 amRNSPrice Monitoring Extension
16th Sep 20207:00 amRNSDemerger of StemPrintER and Distribution in Specie
7th Sep 202011:05 amRNSSecond Price Monitoring Extn
7th Sep 202011:00 amRNSPrice Monitoring Extension
2nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20204:35 pmRNSPrice Monitoring Extension
2nd Sep 20202:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20202:00 pmRNSPrice Monitoring Extension
28th Aug 202012:04 pmRNSHolding(s) in Company
28th Aug 202010:30 amRNSADS Registration Statement Filing Clarification
27th Aug 20204:00 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20207:00 amRNSTiziana CEO Interview
26th Aug 20207:00 amRNSGrant of Options - Director Dealings
24th Aug 20207:00 amRNSPatent Granted for Anti-IL-6/IL-6
21st Aug 20207:00 amRNSPatent Granted for Milciclib
20th Aug 20207:00 amRNSUpdate - Scientific Advisory Board
18th Aug 20209:05 amRNSSecond Price Monitoring Extn
18th Aug 20209:00 amRNSPrice Monitoring Extension
18th Aug 20207:00 amRNSPatent Granted for Foralumab
11th Aug 20208:49 amRNSBTIG's Virtual Biotechnology Conference
10th Aug 20207:00 amRNSHolding(s) in Company
5th Aug 20204:00 pmRNSClosing of $57.25 Million Offering
4th Aug 20207:00 amRNSExpedited Clinical Development Plan
3rd Aug 20207:00 amRNSIssue of Equity
31st Jul 20205:00 pmRNSTotal Voting Rights
31st Jul 20204:41 pmRNSSecond Price Monitoring Extn
31st Jul 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20207:00 amRNSSubmission of a Patent Application for Foralumab
30th Jul 20204:30 pmRNSProposed Admission to the Official List
30th Jul 202011:53 amRNSUpdate on Timings and Corporate Actions
30th Jul 20207:00 amRNSInvestor Webinar to Provide Corporate Updates
29th Jul 20202:05 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
24th Jul 20207:00 amRNSExercise of Warrants and Issue of Equity
20th Jul 20202:51 pmRNSDirector Appointment
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
16th Jul 202011:39 amRNSResult of AGM
16th Jul 20207:00 amRNSSubmission of Patent Application
15th Jul 20204:29 pmRNSChange to ADS Ratio - Updated
15th Jul 20201:00 pmRNSChange to ADS Ratio
14th Jul 20209:06 amRNSSecond Price Monitoring Extn
14th Jul 20209:00 amRNSPrice Monitoring Extension
13th Jul 20204:41 pmRNSSecond Price Monitoring Extn
13th Jul 20204:36 pmRNSPrice Monitoring Extension
10th Jul 20206:01 pmRNSInterview to Air on Bloomberg International
1st Jul 20207:00 amRNSTotal Voting Rights and StemPrintER Update
29th Jun 202011:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.